This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Synergy Pharmaceuticals Announces Data Presentations On Plecanatide And SP-333 At Two Scientific Meetings

Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) today announced presentations on plecanatide and SP-333, its proprietary guanylate cyclase-C (GC-C) agonists in development for gastrointestinal (GI) disorders, will take place at two scientific meetings this month.

Plecanatide, Synergy’s lead GC-C agonist for chronic idiopathic constipation and irritable bowel syndrome with constipation, will be featured in two oral presentations at the United European Gastroenterology (UEG) Week being held October 12-16 in Berlin, Germany.

Updated pre-clinical data on SP-333, the company’s next-generation GC-C agonist being studied for opioid-induced constipation and inflammatory bowel disease, will be featured in two poster presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting being held October 11-16 in San Diego, California.

Plecanatide Oral Presentations - UEG 2013

Abstract: Acceleration of Time to First Bowel Movement in Chronic Idiopathic Constipation (CIC) Patients Receiving Plecanatide in a Large, Multicenter, Dose-Ranging StudyDate & Time: Tuesday, October 15 th, 8:42am – 8:54amAbstract Number: OP155Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan)

Abstract: Plecanatide Produces a Diarrhea Plateau Effect in Chronic Idiopathic Constipation (CIC) PatientsDate & Time: Tuesday, October 15 th, 10:18am – 10:30amAbstract Number: OP163Presenting Author: Ronald P. Fogel, M.D. (Digestive Health Centers of Michigan)

SP-333 Poster Presentations – ACG 2013

Abstract: Oral Treatment with SP-333, an Agonist of Guanylate Cyclase-C, Dramatically Ameliorates Morphine-Induced Bowel Dysfunction in RatsDate & Time: Tuesday, October 15 th, 10:30am – 4:00pmPoster Number: P1091Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.Note: Recipient of, “ACG’s 2013 Presidential Poster Award.” Posters receiving this award accumulated scores in the top five percent of the posters submitted for the ACG Annual Meeting in San Diego, CA.

Abstract: SP-333, a Guanylate Cyclase-C Agonist, Inhibits NF-kB Signaling and Modulates Related Genes and miRNAs Implicated in GI Inflammation and CarcinogenesisDate & Time: Monday, October 14 th, 10:30am – 4:00pmPoster Number: P1049Presenting Author: Kunwar Shailubhai, Ph.D., M.B.A.

About Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders. Synergy's lead proprietary drug candidate, plecanatide, is a synthetic analog of the human GI hormone, uroguanylin, and functions by activating the guanylate cyclase-C (GC-C) receptor on epithelial cells of the GI tract. In early 2013, Synergy announced positive results from a large multicenter trial of plecanatide in patients with chronic idiopathic constipation (CIC) and recently completed an end-of-phase 2 meeting with the U.S. Food and Drug Administration (FDA) covering the registration program for plecanatide to treat CIC. The company plans to initiate the phase 3 registration trial for plecanatide in CIC this quarter. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), recently announcing that it had reached the halfway mark for total enrollment in a plecanatide phase 2b clinical trial in patients with IBS-C. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat opioid-induced constipation and inflammatory bowel disease. SP-333 has completed a phase I study in healthy volunteers and will enter phase 2 trials for OIC in the fourth quarter of 2013. More information is available at .

Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs